Beyond the Ovaries: The Scientific Shift from PCOS to PMOS For more than a century, one of the most prevalent hormonal disorders affecting people worldwide has … Read more
For millions of Americans living with obesity, the arrival of GLP-1 receptor agonists has felt like a medical turning point. These medications—including household names like Wegovy … Read more
For more than half a century, the biological blueprint for how the human body stores and releases sugar was considered a settled matter. Textbooks taught a … Read more
For millions of people living in resource-limited regions, the path from a persistent cough to a tuberculosis (TB) diagnosis is often blocked by a logistical wall. … Read more
The arrival of semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Ozempic and Wegovy—has been hailed as a paradigm shift in the treatment of type 2 … Read more
Medical breakthroughs rarely follow a straight line. Often, they happen in the periphery—a side effect noticed during a trial for something else, or a pattern emerging … Read more
For decades, the medical community has viewed diabetes primarily as a metabolic struggle—a battle of blood sugar, insulin resistance, and organ protection. But a massive new … Read more
The landscape of the multi-billion-dollar GLP-1 receptor agonist market is shifting as the first significant regulatory hurdle for a generic version of semaglutide has been cleared. … Read more
At 38, Liesanne leads a life that appears, on the surface, to be one of modern Amsterdam success. She manages a data department at ABN Amro, … Read more
Type 2 diabetes is rarely a sudden event. It does not begin with a dramatic spike in blood sugar or a sudden onset of symptoms. Instead, … Read more
For decades, the switch from sugar to diet alternatives has been marketed as a simple mathematical trade-off: enjoy the sweetness without the calories. Still, emerging research … Read more
For millions of people living with type 2 diabetes, the daily mental load is often dominated by macronutrients. The focus is almost always on the “big … Read more